Published in Gene Therapy Weekly, October 19th, 1998
The U.S. patent describes how purine derivatives, a class of drug compounds which includes Neotrofin (AIT-082, leteprinim potassium), can be used to selectively control "turning on or off of genes" for the protein molecules involved in nerve regeneration.
This patent represents a significant step forward in the treatment of neurodegenerative diseases utilizing a convenient oral medication to replace or augment the presence of neurotrophic factors in the brain and spinal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.